Gabapentin (Neurontin) Dosing for Psychiatric Disorders
Gabapentin is NOT FDA-approved for any psychiatric disorder, and the evidence does not support its routine use for most psychiatric conditions including major depressive disorder, bipolar disorder, PTSD, or OCD 1, 2.
Critical Context
The provided evidence consists primarily of neuropathic pain guidelines [@1-6@], which are not applicable to psychiatric indications. The FDA label 1 only approves gabapentin for postherpetic neuralgia and epilepsy—no psychiatric disorders are approved indications.
Evidence-Based Psychiatric Uses (Limited)
Alcohol Use Disorder (Only Strong Evidence)
- This is the only psychiatric indication with sufficient evidence 2
- Dosing extrapolated from research: typically 300-1800 mg/day in divided doses
- Start: 300 mg at bedtime or 100-300 mg three times daily
- Titrate gradually by 100-300 mg every 1-7 days as tolerated
Social Anxiety Disorder & Severe Panic Disorder (Third-Line Only)
- Consider only after failure of first- and second-line treatments 2
- Research doses: 900-3600 mg/day in divided doses
- Mean effective dose in studies: approximately 1310-1725 mg/day 3, 4
Conditions WITHOUT Supporting Evidence
Do not use gabapentin for 2:
- Major depressive disorder
- Bipolar disorder (despite older open-label studies 3, 5, 4)
- PTSD
- OCD
- Stimulant use disorder
- Opioid withdrawal
Practical Dosing Algorithm (When Use is Justified)
Starting dose:
- 100-300 mg at bedtime OR
- 100-300 mg three times daily
Titration:
- Increase by 100-300 mg every 1-7 days
- Monitor for dizziness, sedation, mental clouding (especially problematic in psychiatric patients)
Target range (based on research):
- 900-1800 mg/day in 3 divided doses
- Some studies used up to 3600 mg/day, but higher doses show no consistent additional benefit
Maximum interval between doses: 12 hours
Critical Safety Warnings
High-Risk Populations
Gabapentin carries significant risks in psychiatric patients 2, 6:
- Highest risk: Patients with substance use disorder history
- Concomitant CNS depressants: 58.4% of psychiatric gabapentin prescriptions involve concurrent opioids, benzodiazepines, or other CNS depressants 6
- FDA warning about respiratory depression when combined with CNS depressants
Renal Adjustment Required
Dose reduction mandatory in renal impairment 1:
- CrCl ≥60: 900-3600 mg/day
- CrCl 30-59: 400-1400 mg/day
- CrCl 15-29: 200-700 mg/day
- CrCl <15: 100-300 mg/day
Discontinuation
Taper over minimum 1 week to avoid withdrawal 1
Clinical Reality Check
The evidence reveals a concerning pattern: <1% of gabapentin prescriptions are for FDA-approved indications 6, with widespread off-label psychiatric use despite lack of supporting evidence. Most prescriptions come from primary care (34.9%) and non-specialty providers (48.1%), not psychiatrists 6.
Bottom line: Unless treating alcohol use disorder or as a third-line agent for severe anxiety disorders after multiple treatment failures, gabapentin should not be prescribed for psychiatric conditions. The risk-benefit ratio does not favor its use, particularly given high rates of concomitant CNS depressant use in psychiatric populations 2, 6.